NeuroDerm Announces Extraordinary General Meeting of Shareholders for Ratification of Election of External Directors and Adoption of Compensation Policy
January 19, 2015 11:15 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Jan. 19, 2015 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Topline Results of Phase IIa Pharmacokinetic Study of ND0612H and ND0612L, Continuous, Subcutaneously Delivered Levodopa/Carbidopa for the Treatment of Parkinson's Disease
December 30, 2014 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 30, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical-stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm Announces Third Quarter 2014 Financial Results and Provides a Corporate Update
December 18, 2014 07:00 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 18, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced...
NeuroDerm CEO to Present at Oppenheimer Healthcare Conference on December 10, 2014
December 05, 2014 08:53 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Dec. 5, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced that...
NeuroDerm Announces Pricing of Initial Public Offering
November 14, 2014 00:27 ET
|
NeuroDerm Ltd.
REHOVOT, Israel, Nov. 14, 2014 (GLOBE NEWSWIRE) -- NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the pricing of...